Perifosine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Perifosine
Perifosine.svg
Identifiers
CAS number 157716-52-4 YesY
PubChem 148177
ChemSpider 130628
ChEMBL CHEMBL372764
Jmol-3D images Image 1
Properties
Molecular formula C25H52NO4P
Molar mass 461.66 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Perifosine (also KRX-0401) is a drug candidate being developed for a variety of cancer indications.

It is an alkylphospholipid (octadecyl-(1,1-dimethyl-4-piperidylio) phosphate)[1] Perifosine is structurally related to miltefosine. It acts as an Akt inhibitor and a PI3K inhibitor.

It was being developed by Keryx Biopharmaceuticals who have licenced it from Æterna Zentaris Inc.[2]

In 2010 perifosine has reached phase II.[3] In one phase II trial for metastatic colon cancer perifosine doubled time to progression.[2]

It has orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU.[4]

In 2011 it was in a phase III trial for colorectal cancer,[5] and another for multiple myeloma.[4][6] On April 2, 2012, it was announced that perifosine failed its phase III clinical trial for treatment of colon cancer.[7] Detailed results were released in June 2012.[8] On March 11, 2013 Aeterna Zentaris announced the discontinuing of Phase 3 clinical trial of perifosine for the treatment of relapsed and refractory multiple myeloma http://www.aezsinc.com/en/page.php?p=60&q=550.

References[edit]